Menu

Parkinson’s Patient Transplanted with Neurons Derived from iPSCs

This is the first time researchers have tested the use of the reprogrammed stem cells in the human brain.

Nov 14, 2018
Ashley P. Taylor

ABOVE: © ISTOCK.COM, MUZON

In October, researchers at Kyoto University transplanted cells generated from induced pluripotent stem cells into the brain of a man with Parkinson’s disease, the scientists reported Friday (November 9) at a press conference. This is the first time that researchers have tested the use of iPSCs in the human brain, and Parkinson’s disease is only among a handful of conditions for which iPSC-based therapies have been tested in humans at all, Nature reports.

In Parkinson’s disease, cells that produce the neurotransmitter dopamine die off, resulting in tremors and other movement problems. Although there are treatments that can alleviate some symptoms, there is currently no cure for the disease.  

The transplanted cells in this treatment are precursors to dopamine-producing neurons, and the hope is that they will restore the dopamine deficit and relieve symptoms. A very similar procedure reduced movement difficulties in monkeys whose dopaminergic neurons had been experimentally poisoned to model Parkinson’s disease. 

See “First iPS Cell Trial for Heart Disease Raises Excitement, Concern

Kyoto University stem cell researcher Jun Takahashi and colleagues began with a stock of iPSCs, which they had previously reprogrammed from an anonymous donor’s skin cells. They then differentiated the iPSCs into dopaminergic-neuron precursors. In a three-hour surgery, neurosurgeon Takayuki Kikuchi implanted 2.4 million of the precursor cells into 12 sites in the brain. 

“The patient is doing well and there have been no major adverse reactions so far,” Takahashi tells Nature. If all goes well, in six months doctors will implant another dose of neurons into the patient’s brain.

In the future, the researchers plan to give the treatment to six other Parkinson’s disease patients.

“The best scenario is to see patients improve to the extent they do not have to take any medicine,” Takahashi tells The Japan Times.

December 2018

Invisible Borders

An emerging appreciation for membraneless organelles and the liquid dynamics that shape them

Marketplace

Sponsored Product Updates

Rapid ELISA-Based Measurement Of Protein Phosphorylation
Rapid ELISA-Based Measurement Of Protein Phosphorylation
In this article, RayBiotech will present a study in which the phosphorylation of two proteins, STAT1 (Tyr701) and Mek1 (Ser217/221), is detected in response to various agonists. Data from the RayBio® Phosphorylation ELISA kits will be compared to traditional immunoblotting.
Protein Sample Quality Identification and Evaluation
Protein Sample Quality Identification and Evaluation
Checking the quality of your protein before and during your process gives you the highest chance of getting the consistent results. Learn how to evaluate the quality of your protein samples with this application note from NanoTemper!
Using CDD Vault to Manage Redbrick Molecular Ltd. Catalogues - A Case Study
Using CDD Vault to Manage Redbrick Molecular Ltd. Catalogues - A Case Study
Check out this case study to find out why Redbrick Molecular Ltd. chose CDD Vault as their database and informatics platform, and how they made use of the CDD Vault to implement a complex catalogue in a simple way.
New automated N-glycan profiling web app shaves days off of data interpretation for glycobiologists
New automated N-glycan profiling web app shaves days off of data interpretation for glycobiologists
The first automated, web-based application that enables routine use of enzymatic digestions to improve N-glycan analyses from New England Biolabs (NEB). This software not only saves precious times for glycobiologists who are more attuned to traditional methods, but also provides the most accurate interpretation of glycan enzymatic digestion data on the market.